OPKO Health, Inc. (NASDAQ:OPK – Get Free Report) reached a new 52-week high during mid-day trading on Tuesday. The stock traded as high as $1.78 and last traded at $1.7950, with a volume of 273,701 shares. The stock had previously closed at $1.72.
Analyst Ratings Changes
OPK has been the topic of several research analyst reports. Zacks Research raised OPKO Health from a “hold” rating to a “strong-buy” rating in a research note on Monday, September 28th. UBS Group set a $4.00 target price on OPKO Health in a research note on Friday, October 16th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of OPKO Health in a research report on Thursday, August 13th. Barrington Research upgraded shares of OPKO Health from a “market perform” rating to an “outperform” rating and set a $2.25 price objective for the company in a report on Friday, October 16th. Finally, Piper Sandler reiterated an “overweight” rating and set a $4.00 price target (up from $3.00) on shares of OPKO Health in a report on Friday, October 16th. One analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $3.42.
View Our Latest Report on OPKO Health
OPKO Health Price Performance
The stock has a market cap of $1.32 billion, a P/E ratio of -19.72 and a beta of 1.51. The company’s fifty day simple moving average is $1.57 and its 200-day simple moving average is $1.35. The company has a current ratio of 3.35, a quick ratio of 2.93 and a debt-to-equity ratio of 0.28.
Institutional Investors Weigh In On OPKO Health
Several large investors have recently modified their holdings of OPK. BlackRock Inc. bought a new position in OPKO Health during the 2nd quarter valued at about $55,468,000. AWM Investment Company Inc. acquired a new position in shares of OPKO Health during the second quarter valued at $3,165,000. Bank of New York Mellon Corp bought a new position in shares of OPKO Health in the 2nd quarter valued at about $1,995,000. Bank of America Corp DE acquired a new stake in OPKO Health during the 2nd quarter worth $1,194,000. Finally, Legal & General Group Plc bought a new position in OPKO Health during the second quarter worth about $520,000. 64.63% of the stock is currently owned by institutional investors.
OPKO Health Company Profile
OPKO Health, Inc is a healthcare company focused on diagnostics and pharmaceuticals. Through its BioReference Laboratories business, the company provides clinical laboratory services, including routine testing, specialty diagnostics, genetic testing and oncology-related laboratory services. OPKO also develops diagnostic products, including the 4Kscore test, a blood test designed to help assess the risk of aggressive prostate cancer.
In pharmaceuticals, OPKO develops treatments for kidney disease, endocrine disorders and other conditions.
Featured Stories
- Five stocks we like better than OPKO Health
- Are the Fears Around Alphabet’s Search Slowdown Warranted?
- Streaming Success: Fox Corp Channels Tubi For Q1 Earnings Beat
- Caterpillar’s Sell-Off: Is the Market Missing Its AI Power Play?
- Check Point’s Turnaround Could Be Closer Than Investors Think
Receive News & Ratings for OPKO Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OPKO Health and related companies with MarketBeat.com's FREE daily email newsletter.
